medigraphic.com
Boletín Clínico de la Asociación Médica del Hospital Infantil del Estado de Sonora

2023, Number 2

<< Back Next >>

Bol Clin Hosp Infant Edo Son 2023; 40 (2)

BCG vaccine, tuberculosis protection and other benefits

Orozco AI, Aguilar MKD, Reyes GU, Reyes HKL, Vargas MME, Merlo PM, Juárez CCE, Gutierrez GVM, Escalera AP, Ayuzo VC, Gómez RAA, Galaviz BMJ, Baeza CJA

Language: Spanish
References: 22
Page: 38-43
PDF size: 323.16 Kb.


ABSTRACT

Tuberculosis is a chronic infectious-contagious disease that primarily affects the lungs but can affect any part of the body. BCG or Bacille Calmette-Guerin is a vaccine against tuberculosis disease. It is a preparation of live attenuated bacteria derived from a culture of Bacille Calmette-Guerin (Mycobacterium bovis). The BCG vaccine, in addition to its specific protective effect against tuberculosis, stimulates trained innate immunity, resulting in protective effects against other infectious and non-infectious diseases other than tuberculosis. Specific protection against the disease is carried out with BCG vaccination in the newborn. This is a basic review of benefit concepts of this vaccine to avoid tuberculosis and its application in other diseases.


REFERENCES

  1. Orozco-Andrade I. Tuberculosis. Tomo II. Publicaciónindependiente; 2023. ISBN: 9798393051259.

  2. WHO operational handbook on tuberculosis. Module5: management of tuberculosis in children andadolescents. Geneva: World Health Organization;2022. Licence: CC BY-NC-SA 3.0 IGO.

  3. McKenna L, Sari AH, Mane S, Scardigli A, Brigden G,Rouzier V, Becerra MC, Hesseling AC, Amanullah F.Pediatric Tuberculosis Research and Development:Progress, Priorities and Funding Opportunities. Pathogens.2022 Jan 21; 11(2): 128.

  4. Global tuberculosis report 2021. Geneva: WorldHealth Organization; 2021. Licence: CC BY-NC-SA3.0 IGO.

  5. WHO. Boletín epidemiológico semanal. 2018, 93(8):73-96.

  6. Mangtani P, et al. Protection by BCG vaccineagainst tuberculosis: A systematic review of randomizedcontrolled trials. Clin Infect Dis. 2014; 58(4):470-480.

  7. Abubakar I, et al. Systematic review and metaanalysisof the current evidence on the duration ofprotection by bacillus Calmette–Guérin vaccinationagainst tuberculosis. Health Technol Assess. 2013;17(37 ).

  8. Trunz BB, et al. Effect of BCG vaccination on childhoodtuberculous meningitis and miliary tuberculosisworldwide: a meta-analysis and assessment ofcost-effectiveness. Lancet. 2006; 367(9517): 1173-1180.

  9. Roy A, et al. Effect of BCG vaccination againstMycobacterium tuberculosis infection in children:systematic review and meta-analysis. BMJ. 2014;349(aug04_5): g4643.

  10. Kowalewicz-Kulbat M, Locht C. BCG and protectionagainst inflammatory and auto-immune diseases.Expert Rev Vaccines. 2017l; 16(7): 1-10.

  11. Kühtreiber WM, Faustman DL. BCG Therapy forType 1 Diabetes: Restoration of Balanced Immunityand Metabolism. Trends Endocrinol Metab. 2019Feb; 30(2): 80-92.

  12. Merle CS et al. BCG vaccination and leprosy protection:review of current evidence and status of BCGin leprosy control. Expert Rev Vaccines. 2010; 9(2):209-222.

  13. Poobalan A, et al. Systematic review on the effectivenessand efficacy of BCG against leprosy. 2017,published summary in the SAGE BCG workingGroup report.

  14. WHO. BCG Working Group Report, SAGE meetingOctober 2017.

  15. Berendsen LM, Bjerregård OC, Bles P, Jensen AG,Poul-Erik Kofoed, Hilton Whittle A, et al. MaternalPriming: Bacillus Calmette-Guérin (BCG) VaccineScarring in Mothers Enhances the Survival of TheirChild With a BCG Vaccine Scar. Jour Pedia Infec DisSoc. 2020 junio; 9(2): 166-72.

  16. Bright M, Curtis N, Messina N. The role of antibodiesin bacille calmette guérin-mediated immuneresponses and protection against tuberculosis inhumans: A systematic review. Tuberculosis. 2020.doi: https://doi.org/10.1016/j.tube.2020.101947

  17. Gámez-González LB, Hamada H, Llamas-GuillenBA, Ruiz-Fernández M, Yamazaki NM. BCG andKawasaki disease in Mexico and Japan, HumanVaccines & Immunotherapeutics. 2017; 13(5):1091-3.

  18. Pittet LF, et al. BRACE Trial Consortium Group. RandomizedTrial of BCG Vaccine to Protect againstCovid-19 in Health Care Workers. N Engl J Med.2023 Apr 27; 388(17): 1582-1596.

  19. Kantor, I. ¿BCG versus COVID-19? MEDICINA (BuenosAires). 2020; 80: 292-294.

  20. Giamarellos-Bourboulis, et al. Activate: RandomizedClinical Trial of BCG Vaccination against Infectionin the Elderly. 2020 octubre 5; 183: 315-323.

  21. Escobara L, Molina-Cruz A, Barillas-Mury C. BCGvaccine protection from severe coronavirus disease2019 (COVID-19). PNAS. 2020 noviembre 3;117(44): 27741-27742.

  22. Moorlag, et al. Safety and COVID-19 Symptoms inIndividuals Recently Vaccinated with BCG: a RetrospectiveCohort Study. Cell Reports Medicine.2020 agosto 25; 1: 100073.




2020     |     www.medigraphic.com